Cary, NC -- (ReleaseWire) -- 07/11/2007 -- Cornerstone BioPharma™, the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the respiratory arena, today announced it has signed a co-promotion agreement with SJ Pharmaceuticals (SJP). This agreement names SJP as a partner in the promotion of Spectracef®, a broad spectrum, third-generation cephalosporin.

Essentially, when a patient is diagnosed with a bacterial infection, Spectracef® is used to help the body fight off pathogens. It is an oral antibiotic used to treat such things as Community-Acquired Pneumonia (CAP), Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Pharyngitis/Tonsillitis, and Uncomplicated Skin and Skin-Structure Infections (USSSI). Spectracef®, a part of the major therapeutic category of antibiotics, will be beneficial to most primary care physicians as the discovery and development of new antibiotics becomes more valuable in the medical field.

Cornerstone obtained exclusive U.S. licensing rights for Spectracef® from leading Japanese pharmaceutical company Meiji Seika Kaisha in October 2006 and began promotion through their sales force shortly thereafter. Commencing immediately, the SJ Pharmaceuticals sales force will co-promote Spectracef®, significantly increasing awareness, promotional efforts and reach of the medication. The total worldwide market for antibiotic treatments was $25 billion in 2005, with $4.7 billion allocated to the respiratory antibiotic market. Cornerstone's new partnership with SJP represents expansion into the $1.5 billion U.S. oral solid cephalosporin market and will serve to increase the recognition of Spectacef® among healthcare providers.

Commenting on the agreement, SJ Pharmaceuticals President Terri Jackson Wade said, "Spectracef is a proven cephalosporin antibiotic with, we believe, untapped potential. The SJP sales team has tremendous depth in the respiratory category and the Southeast, and we are thrilled to be leveraging our credibility and expertise in this partnership with Cornerstone BioPharma."

"SJP's experienced sales force is well entrenched in the market and will allow us to reach more healthcare providers. There is a strong need for antibiotic options in light of the resistance issues faced by today's healthcare community. With SJP's sales force, more practitioners will learn about Spectracef® as a highly potent option for respiratory and skin diseases," said Craig Collard, President and CEO of Cornerstone BioPharma.

About Cornerstone
Cornerstone BioPharma, Inc. (www.cornerstonebiopharma.com), located next to North Carolina's Research Triangle Park, is an emerging specialty pharmaceutical company that is currently focused on the development and commercialization of niche prescription medications in the respiratory arena. Cornerstone is actively engaged in strategic licensing of additional prescription products through acquisitions, strategic partnerships and new product development.

About SJ Pharmaceuticals
SJ Pharmaceuticals, LLC (www.sjpharma.com), is a dynamic family business committed to the development and marketing of prescription pharmaceutical products. With products in the respiratory, urology, and cardiovascular therapeutic categories, SJP actively seeks to advance treatment options for providers and their patients through the commercialization of innovative yet practical pharmaceutical products. SJP continues to build on its 30 plus year heritage as it cultivates a premier sales and marketing organization.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Cornerstone BioPharma, J-Med Pharmaceuticals and Sovereign Pharmaceuticals Settle Pending Litigation Concerning U.S. Patent No. 6,270,796 and AlleRx™ Dose Pack

Cary, NC -- (ReleaseWire) -- 01/25/2007 -- Cornerstone BioPharma ("Cornerstone") of Cary, North Carolina, and J-Med Pharmaceuticals ("J-Med") of Boston, Massachusetts, today announced that they have settled pending patent litigation with Sovereign Pharmaceuticals, Ltd., ("Sovereign") of Fort Worth, Texas, in connection with U.S. Patent No. 6,270,796 ("the '796 patent"). The litigation was brought by the patent owner J-Med and licensee Cornerstone, who markets and sells the AlleRx™ Dose Pack.

AlleRx™ Dose Pack is one of three respiratory focused brands in the Cornerstone product line. The AlleRx™ Dose Pack is a prescribed AM/PM dosing regimen, available in a 10-day and 30-day supply, indicated for relief of the symptoms of vasomotor rhinitis and allergic rhinitis (runny nose associated with high pollen counts and specific year-round allergens). Over 30 million people in the U.S. have been diagnosed with allergic rhinitis alone.

"Cornerstone is dedicated to the development and commercialization of niche respiratory products that serve both the healthcare professionals and their patients," said Craig Collard, President and CEO of Cornerstone BioPharma. "We will continue to defend the licensed invention of the AlleRx™ Dose Pack against all infringers," he added.

As part of the settlement, Sovereign entered into a consent judgment confirming the validity and enforceability of the '796 patent. Sovereign will cease manufacturing a product intended to be packaged in violation of the '796 patent. Sovereign has further agreed to a permanent injunction and admitted that the products they manufactured infringed the '796 patent. Cornerstone and J-Med have agreed to not pursue damages for Sovereign's past infringement.

"The settlement and consent judgment entered by the Court confirm the validity and enforceability of J-Med's '796 patent. With a substantial patent portfolio, J-Med remains dedicated to providing novel therapies to physicians and patients that significantly improve patient care," said Allan Weinstein, M.D., President of J-Med Pharmaceuticals.

By agreement, Cornerstone, J-Med and Sovereign will make no further public announcements about the resolution of the litigation beyond these written statements.

About Cornerstone BioPharma
Cornerstone BioPharma, Inc. (www.cornerstonebiopharma.com), located next to North Carolina's Research Triangle Park, is an emerging specialty pharmaceutical company that is currently focused on the development and commercialization of niche prescription medications in the respiratory arena. Cornerstone is actively engaged in strategic licensing of additional prescription products through acquisitions, strategic partnerships and new product development.

About J-Med
J-Med Pharmaceuticals is a 19-year-old intellectual property pharmaceutical company founded by physicians who invent, develop and patent pharmaceutical products and methods, primarily directed to the treatment of respiratory ailments. J-Med actively licenses its patents and patented technologies, and these patent-protected products are manufactured and sold throughout the United States.

About Sovereign
Sovereign Pharmaceuticals (www.sovpharm.com), established 1990, is a privately owned and operated company. Sovereign's committed team of employees excels in cGMP training and is focused on delivering high quality products in a timely manner. During the past three years Sovereign has upgraded equipment and facilities to meet the demands of its customers. The firm has recently completed a major expansion of its Research and Development Department, moving that department to the state-of-the-art 7,200 square foot facility and employing several scientists and additional support personnel.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Triangle-based specialty pharmaceutical company to serve $1.3 billion per year oral cephalosporin market

Cary, NC -- (ReleaseWire) -- 11/13/2006 -- Cornerstone BioPharma™, the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the respiratory arena, today announced the company has obtained exclusive U.S. licensing rights from leading Japanese pharmaceutical company Meiji Seika Kaisha for Spectracef (cefditoren pivoxil).

Spectracef is a cephalosporin oral antibiotic used to treat adults and adolescents (12 years of age or older) with certain bacterial infections of the lungs, throat and skin. The drug is indicated to treat Community-Acquired Pneumonia (CAP), Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Pharyngitis/Tonsillitis and Uncomplicated Skin and Skin-Structure Infections (USSSI). Effective immediately, Cornerstone BioPharma's seasoned sales force will begin promotion and sale of Spectracef to primary care providers, allergists and otolaryngologists nationwide.

"We are pleased and honored to be partnering with such a well-respected leader in the pharmaceutical industry such as Meiji Seika Kaisha," commented Craig Collard, CEO of Cornerstone BioPharma. "Meiji Seika Kaisha's Spectracef represents tremendous potential and opportunity for us. In just the past year alone 35 million oral cephalosporin pills were prescribed pushing the market well over the $1.3 billion mark."

"By strategically aligning our product, Spectracef, with Cornerstone BioPharma's proven sales organization, we are in a position to make a tremendous positive impact on patients in the U.S. suffering from certain bacterial infections," commented A Otsubo, Meiji Seika Kaisha executive vice president. "We are pleased and excited to have partnered with Cornerstone BioPharma and look forward to exploring ways through which we can expand upon this relationship in the future."

Cornerstone BioPharma also promotes the AlleRx ™ product line for the temporary relief of symptoms associated with allergic rhinitis, vasomotor rhinitis, and the common cold. Currently, the US allergy market exceeds $3.3 billion in annual sales as more than 50 million Americans suffer from allergy symptoms.

About Cornerstone
Cornerstone BioPharma, Inc. (www.cornerstonebiopharma.com), located next to North Carolina's Research Triangle Park, is an emerging specialty pharmaceutical company that is currently focused on the development and commercialization of niche prescription medications in the respiratory arena. Cornerstone is actively engaged in strategic licensing of additional prescription products through acquisitions, strategic partnerships and new product development.

About Meiji Seika Kaisha
Since its establishment in 1916, Meiji Seika Kaisha, Ltd. (http://www.meiji.co.jp/en) has long played a part in helping people lead happier and more fulfilling lives. The pharmaceutical company concentrates on providing anti-infectives and central nervous system drugs for the treatment of diseases, and it has a growing line of generic drugs. As an organization that is closely linked to the preservation of good health and life, Meiji Seika will continue to fulfill its social responsibility and provide products that help its customers lead fulfilling lives while adhering to the highest ethical standards.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm